Observational studyPituitary2026
The metabolic effects of glucocorticoid replacement therapy in patients with secondary adrenal insufficiency due to hypothalamic-pituitary diseases: results from a retrospective and longitudinal study.
Observational study in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSecondary adrenal insufficiency (SAI) is a complex endocrine disorder. Glucocorticoid (GC) replacement therapy is crucial for ensuring patient survival and guaranteeing an adequate quality of life. GC replacement therapy requires a balance between undertreatment, with the consequent risk of adrenal crisis, and overtreatment, which can have long-term effects on the metabolic and cardiovascular systems.
methodsWe conducted a retrospective, longitudinal, observational study on 140 patients affected by pituitary disease with at least 3 years of follow-up. Patients were consecutively included in the study with a ratio 1:1, considering patients affected by SAI and who were therefore on GCs replacement therapy, and patients with pituitary disease without SAI (controls).
resultsWorsening of glucose metabolism occurred in 29 patients with SAI (64.4%) and in 16 controls (35.6%, p = 0.019). Worsening of lipid metabolism occurred in 52 patients with SAI (56.5%) and in 40 controls (43.5% p = 0.033). GC replacement therapy (p = 0.014, OR: 2.3, 95%IC: 1.1-4.9), higher fasting glycaemia at baseline (p = 0.04, OR: 7.6, 95%IC: 2.3-25.4), IGT/T2DM at baseline (p = 0.016, OR: 8.6, 95%IC: 0.8-57) were the main risk factors for the worsening of glucose metabolism at 3-year follow-up. TSH deficit remained the only risk factor for the worsening of lipid profile (p < 0.001, OR: 2.9, 95%IC: 1.3-6.5).
conclusionOur study proved that GCs replacement therapy may be associated with a worsening of glucose metabolism, particularly in patients already affected by IGT/T2DM. Tailored and holistic management is essential for the management of GCs replacement therapy, in patients with other metabolic disorders and pituitary hormone deficits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.